Boron neutron capture therapy of a murine mammary carcinoma using a lipophilic carboranyltetraphenylporphyrin

Radiation Research

Volumn 155, Issue 4, 2001, Pages 603-610

  Miura, M ^a   Morris, G M ^a   Micca, P L ^a   Lombardo, D T ^a   Youngs, K M ^a   Kalef Ezra, J A ^a   Hoch, D A ^a   Slatkin, D N ^a   Ma, R ^a   Coderre, J A ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORON 10; CARBORANE DERIVATIVE; CARBORANYLTETRAPHENYLPORPHYRIN; PORPHYRIN DERIVATIVE; TETRAPHENYLBORON; UNCLASSIFIED DRUG; 4 BORONOPHENYLALANINE; 4-BORONOPHENYLALANINE; BORANE DERIVATIVE; BOROCAPTATE; BORON; BORON DERIVATIVE; DRUG CARRIER; DRUG DERIVATIVE; PHENYLALANINE; THIOL DERIVATIVE;

ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CONTROL; CANCER MODEL; CHEMICAL STRUCTURE; CONTROLLED STUDY; FEMALE; LIPOPHILICITY; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; TISSUE DIFFERENTIATION; X IRRADIATION; ANIMAL; COMPARATIVE STUDY; EXPERIMENTAL NEOPLASM; HINDLIMB; HYDROPHOBICITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE STRAIN; THORAX; TISSUE DISTRIBUTION;

MURINAE; RODENTIA;

ANIMAL; BOROHYDRIDES; BORON; BORON COMPOUNDS; BORON NEUTRON CAPTURE THERAPY; COMPARATIVE STUDY; DRUG CARRIERS; FEMALE; HINDLIMB; HYDROPHOBICITY; INJECTIONS, INTRAPERITONEAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; PHENYLALANINE; SULFHYDRYL COMPOUNDS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; THORAX; TISSUE DISTRIBUTION;

EID: 0035093011     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/0033-7587(2001)155[0603:BNCTOA]2.0.CO;2     Document Type: Article

References (26)

1. The radiation biology of boron neutron capture therapy
2. Boron neutron capture therapy for glioblastoma multiforme: Interim results from the phase I/II dose-escalation studies
3. The Finnish boron neutron capture therapy program - An overview on scientific projects
4. A Phase-I dose escalation trial of boron neutron capture therapy for subjects with metastatic subcutaneous melanoma of the extremities
5. 11SH (BSH) in patients with malignant glioma as precondition for boron neutron capture therapy (BNCT)
6. 11SH) in patients with intracranial tumors
7. Neutron capture therapy of the 9L gliosarcoma using the p-boronophenylalanine-fructose complex
8. Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: Boron concentration correlates with tumor cellularity
9. 10B-neutron capture therapy: Enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical calculation
10. Biodistribution and toxicity of 2,4-divinyl-nido-o-carboranyl-deuteroporphyrin IX in mice
11. Uptake of a nido-carboranylporphyrin by human glioma xenografts in athymic nude mice and by syngeneic ovarian carcinomas in immunocompetent mice
12. Toxicology of a boronated porphyrin in dogs
13. Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy: Biodistribution and toxicity in tumor-beating mice
14. Evaluation of carborane-containing porphyrins as tumour targeting agents for boron neutron capture therapy
15. The chemistry of neutron capture therapy
16. Boron neutron capture therapy of a murine melanoma
17. Boron neutron capture of brain tumors: Enhanced survival following intracarotid injection of sodium borocaptate with or without blood-brain barrier disruption
18. Boron neutron capture therapy of intracerebral rat gliosarcomas
19. Pharmacokinetic and tissue distribution studies of the photosensitizer bis(di-isobutyl octadecylsiloxy)silicon 2,3-naphthalocyanine (isoBOSINC) in normal and tumor-bearing rats
20. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture adapted derivative
21. Response of rats skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium
22. 7Li reaction
23. Epithermal beam development at the BMRR: Dosimetric evaluation
24. The IPEMB code of practice for the determination of absorbed dose for x-rays below 300 kV generating potentials (0.035 mm Al-4 mm cu HVL; 10-300 kV generating potential)
25. Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy